Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
BSA approves four new, five reissue concepts

BSA approves four new, five reissue concepts

December 13, 2024
Vol.50 No.46
By Jacquelyn Cobb and Claire Marie Porter
In Brief

VCU awarded $9M from NCI to establish Cancer Control Equity Research Center

December 13, 2024
Vol.50 No.46
In Brief

UCLA’s Christopher Seet receives $2.9M NCI grant to advance cell-based cancer treatments

December 13, 2024
Vol.50 No.46
NCI paylines to drop to 9th percentile amid CRs and uncertainty
NCI

NCI paylines to drop to 9th percentile amid CRs and uncertainty

December 06, 2024
Vol.50 No.45
By Jacquelyn Cobb
An NCI initiative focuses on early-onset cancers

An NCI initiative focuses on early-onset cancers

December 06, 2024
Vol.50 No.45
By Yiqing Wang
In Brief

University of Cincinnati receives $2.3M from NCI to visualize CAR T cells within the body

November 22, 2024
Vol.50 No.44
As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
White House

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

November 15, 2024
Vol.50 No.43
By Paul Goldberg
In Brief

NCI renews IU Simon Comprehensive Cancer Center’s designation

November 15, 2024
Vol.50 No.43
NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

October 25, 2024
Vol.50 No.40
By Claire Marie Porter
Clinical Roundup

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

October 25, 2024
Vol.50 No.40

Posts navigation

Previous1…121314…37Next

Trending Stories

  • Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
  • Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
  • One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
  • Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
  • GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
    Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis
  • As more people are surviving cancer, we must continue funding bold science

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account